- Home
- Companies
- Auro Vaccines LLC
- Products
- Auro - Model PBS VAX - Clinical-Stage ...
Auro - Model PBS VAX - Clinical-Stage Therapeutic Vaccines for HPV
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck cancers.
Program Status:
Candidate HPV vaccines have completed immunogenicity testing in NHPs and a final seven valent vaccine design has been down-selected for cGMP manufacture. Phase I clinical testing is anticipated in 2021.
Unmet Medical Need:
Cervical cancer is the second leading cause of cancer-related mortality in women worldwide, causing about 470,000 deaths per year. In addition, recent studies have shown the same high risk types of HPV are responsible for most head and neck cancers in both women and men. The currently licensed prophylactic HPV vaccines are not effective as therapeutics in infected subjects.